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Abstract
Walleye dermal sarcoma virus is a complex retrovirus that is associated with walleye dermal sarcomas that are seasonal in nature. Fall developing
tumors contain low levels of spliced accessory gene transcripts A and B, suggesting a role for the encoded proteins, Orf A and Orf B, in oncogenesis.
In explanted tumor cells the 35 kDa Orf B accessory protein is localized to the cell periphery in structures similar to focal adhesions and along actin
stress fibers. Similar localization was observed in mammalian cells. The cellular protein, receptor for activated C kinase 1 (RACK1), bound Orf B in
yeast two-hybrid assays and in cell culture. Sequence analysis of walleye RACK1 demonstrated high conservation to other known RACK1
sequences. RACK1 binds to activated protein kinase C (PKC). Orf B associates with PKCα, which is constitutively activated and localized at the
membrane. Activated PKC promoted cell survival, proliferation, and increased cell viability in Orf B-expressing cells.
© 2008 Elsevier Inc. All rights reserved.Keywords: Oncogenesis; Retrovirus; Walleye dermal sarcoma virus; RACK1; PKCIntroduction
Dermal sarcoma in walleye (Sander vitreus) is etiologically
associated with the complex retrovirus, walleye dermal sarcoma
virus (WDSV) (Martineau et al., 1992, 1991; Walker, 1969;
Yamamoto et al., 1985, 1976).Walleye dermal sarcoma (WDS) is
exceptional in its seasonal nature. Tumors first appear on fish in
the fall and are present throughout the winter. During the
spawning period, the following spring, the tumors naturally
regress (Bowser et al., 1988; Bowser and Wooster, 1991). WDS
is efficiently transmitted experimentally to walleye fingerlings by
topical, oral, or intramuscular administration of filtrates prepared
from regressing tumors. In contrast, filtrates from developing
tumors are unable to transmit disease (Bowser et al., 1990;
Bowser et al., 1996; Martineau et al., 1990). Associated with the
seasonal nature of disease are differences in viral gene expression
(Bowser et al., 1996; Quackenbush et al., 1997). The developing
fall tumors only express the spliced accessory gene transcripts, A⁎ Corresponding author. Mailing address: Department of Microbiology,
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doi:10.1016/j.virol.2008.01.034and B, encoding orf a and orf b, while regressing spring tumors
were found to express spliced transcripts, the full-length genomic
RNA, and infectious virus (Bowser et al., 1996; Martineau et al.,
1992; Quackenbush et al., 1997). The presence of only the A and
B transcripts during tumor development led to the hypothesis that
the Orf A and Orf B proteins mediate oncogenesis.
orf a encodes a retroviral cyclin (rv-cyclin or Orf A) protein,
which localizes to the nucleus and interacts with proteins
necessary for transcription (LaPierre et al., 1998; Rovnak et al.,
2001, 2005; Rovnak and Quackenbush, 2002, 2006). Rv-cyclin
functions to negatively regulate viral gene expression through
the direct interaction of its transcription activation domain with
TATA binding protein-associated factor 9 (TAF9) (Rovnak
et al., 2005; Rovnak and Quackenbush, 2006). WDSV rv-cyclin
can induce cell-cycle progression in cyclin deficient yeast and
induce hyperplasia in transgenic mice after wound healing
(Lairmore et al., 2000; LaPierre et al., 1998).
orf b encodes a protein of 306 amino acids with a molecular
mass of 35 kDa and has limited sequence homology to the rv-
cyclin (LaPierre et al., 1999) but no homology with other,
known proteins. WDSV Orf B was found to localize in the
cytoplasm and at the plasma membrane in explanted tumor cells
(Rovnak et al., 2007). Cellular proteins that interact with Orf B
551C.C. Daniels et al. / Virology 375 (2008) 550–560were identified in a yeast 2-hybrid assay, one of which is the
receptor for activated C kinase (RACK1)(see below).
RACK1 is a 36 kDa protein (Ron et al., 1994) composed of
seven WD repeats, domains first identified in the β subunit of
the heterotrimeric G proteins that are important in protein–
protein interactions (Fong et al., 1987; Neer et al., 1994).
RACK1 binds to activated conventional isoforms of protein
kinase C (PKC) and functions as an anchoring protein to
stabilize PKC at the membrane in an active conformation (Dorn
and Mochly-Rosen, 2002; Ron et al., 1994).
PKC comprises a large family of serine–threonine isoenzymes
that contain a regulatory domain and a kinase core. PKCs are
classified into three groups based on the domain composition of
the regulatory component: conventional (α, βI,βII, and γ), novel
(δ, ɛ, η, and θ), and atypical (ζ and ι/λ) (Newton, 2003). PKCs are
involved in a broad array of biological functions such as cell
proliferation, differentiation, survival and apoptosis (Nakashima,
2002; Nishizuka, 1988, 1995). All PKC isoforms associate with
phospholipids in the membrane, and each group has additional
cofactor requirements for full activation. The conventional PKCs
are calcium-dependent (Ca+2) and require binding to diacylgly-Fig. 1. Expression of WDSV Orf B in explanted tumor cells and NIH3T3 cells. (Up
anti-Orf B sera and FITC-conjugated goat anti-rabbit IgG (green). 400× magnification
anti-HA mAb (HA.11) and FITC-conjugated anti-mouse IgG (green). 400× magnificerol (DAG) for activation (Newton, 2003; Nishizuka, 1986).
Novel PKCs are Ca+2-independent but require DAG for acti-
vation, and the atypical isoforms only require phosphatidylserine
for activation (Newton, 2003; Nishizuka, 1984).
In this study we demonstrate a direct interaction of Orf B
with RACK1 and constitutive activation of PKCα in Orf B-
expressing cells. Further, activation of the PKC signaling
pathway is responsible for the ability of Orf B-expressing cells
to survive and proliferate under serum-deprived conditions.
Results
Expression of WDSVOrf B in explanted tumor cells and cell lines
Cells from a regressing tumor were established in vitro after
explanting tumor fragments in culture dishes (Rovnak et al.,
2007). The adherent cells, which include cells of mixed lineages,
were transferred to glass microscope slides, and expression of
WDSV Orf B was evaluated by an immunofluoresence assay
using rabbit anti-Orf B serum. Orf B localized to the plasma
membrane in structures consistent with focal adhesions andper panels) Explanted spring tumor cells were labeled consecutively with rabbit
. (Lower panel) NIH3T3 (left) and NIH3T3–Orf B (right) cells were labeled with
cation. Nuclei were stained with DAPI (blue).
Fig. 2. WDSV Orf B interacts with RACK1. Lysates from NIH3T3 cells and
3T3 cells stably expressing Orf B (NIH3T3–Orf B) were immunoprecipitated
with mouse anti-RACK1 antibody or normal mouse serum (NMS). HA-tagged
Orf B was detected with anti-HA antibody (12CA5). Lysate represents 4% of the
total amount used for immunoprecipitation.
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Stable expression of Orf B was established in NIH3T3 cells,
Chinese hamster ovary cells (CHO), and canine fibroblast cells
(Cf2Th) by transfection with an Orf B expression construct
(pKH3–Orf B) and selection for neomycin resistance. Orf B
expression in the cell lines is localized to the cytoplasm and
associated with the membrane and stress fibers, similar to that
observed in the explanted tumor cells (Fig. 1, NIH3T3–Orf B
cells—lower panel and data not shown). Orf B is also present in
the nucleus of these cells.Fig. 3. Amino acid sequence alignment of walleye RACK1with human, mouse, and z
shaded, and non-identical residues are unshaded. Positions of the seven WD repeatsWDSV Orf B interacts with RACK1
A yeast two-hybrid assay was used to identify cellular
proteins that interact with WDSV Orf B. WDSV Orf B was
fused to the GAL4 DNA binding domain (GAL4 DBD) and
used as the bait for screening a human cDNA library. The
sequence of the walleye genome is not known, so a human
cDNA library was used to facilitate identification of Orf B
interacting proteins. Saccharomyces cerevisiae strain Y190,
harboring the HIS3 and lacZ reporter genes under the control of
the GAL1 UAS, were co-transformed with a HeLa cDNA
library and the GAL4 DBD-Orf B construct. Positive HIS3
transformants were screened for β-galactosidase activity by
colony-lift filter assay. Sequence analysis of DNA isolated from
ten β-galactosidase positive colonies revealed that two clones
contained partial cDNAs of the human RACK1 gene encoding
amino acids 87–317 or 139–317, limiting potential Orf B
interaction to the last 178 amino acids of RACK1. This region
of RACK1 encompasses WD repeats 5 through 7.
To verify the interaction of WDSV Orf B with RACK1 in
vertebrate cells, immunoprecipitation (IP) assays were used.ebrafish RACK1. Identical residues are darkly shaded, similar residues are lightly
(WD1–7) are indicated with arrows.
Fig. 5. WDSV Orf B interacts with PKCα. Lysates from NIH3T3 cells stably
expressing Orf B (NIH3T3–Orf B) and NIH3T3 control cells (NIH3T3) were
immunoprecipitated with rabbit anti-PKCα antibody or with rabbit anti-PKCδ
antibody. HA-tagged Orf B was detected with anti-HA (12CA5) MAb. Lysate
represents 4% of total amount used for immunoprecipitation.
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antibody or normal mouse serum (NMS) followed by western
blot analysis with anti-HA antibody (12CA5) to detect
expressed, HA-tagged Orf B. Orf B was co-immunoprecipitated
(coIP) with RACK1 from cells that stably express WDSV Orf B
(NIH3T3–Orf B) (Fig. 2). In addition, Orf B was coIPed with
RACK1 from lysates of Cf2Th and CHO cells that stably
express Orf B and HeLa cells transiently transfected with an Orf
B expression construct, pKH3-Orf B (data not shown).
The walleye orthologue of human RACK1 was cloned to
confirm its interaction with Orf B. RACK1 is highly conserved
across species (Chou et al., 1999; Kwak et al., 1997). Therefore,
degenerate polymerase chain reaction (PCR) primers, based on
highly conserved regions of human, mouse, fugu, and zebrafish
RACK1, were used in a reverse transcriptase polymerase chain
reaction (RT-PCR) reaction followed by 5′ rapid amplification of
cDNA ends (5′ RACE) to amplify walleye RACK1. Walleye
RACK1was found to be 317 amino acids in length and predicted
to encode a 36 kDa protein. The amino acid sequence of walleye
RACK1 is 97% identical to zebrafish and 96% identical tomouse
and human RACK1 (Fig. 3). The seven conserved WD repeats
were identified in walleye RACK1 by amino acid alignment with
human, mouse, and zebrafish RACK1 (Fig. 3). The WD repeats
in RACK1 are predicted to form a seven-bladed propeller
structure similar to that described for the β subunit of G proteins
(Garcia-Higuera et al., 1996). The WD repeats serve as docking
sites for binding of multiple proteins (Ron and Mochly-Rosen,
1994; Schechtman and Mochly-Rosen, 2001).
coIP assays were used to test for the interaction of walleye
RACK1 with WDSV Orf B. Cell lysates from HeLa cells co-
transfected with FLAG-tagged walleye RACK1 (pFLAG-
wRACK1) and HA-tagged Orf B (pKH3-Orf B) expression
constructs or empty vectors were incubated with anti-HA
(12CA5) or anti-FLAG antibodies and protein G sepharose. IP
protein complexes were separated by SDS-PAGE and westernFig. 4. A. Co-immunoprecipitation of Orf B and walleye RACK1 from HeLa
cell lysates. Lysates from HeLa cells co-transfected with HA-tagged Orf–B
(pKH3–Orf B) and FLAG-tagged walleye RACK1 (pFLAG–wRACK1) or
empty vectors pKH3 and pFLAG were immunoprecipitated with anti-HA or
anti-FLAG antibodies. HA-tagged Orf B was detected with anti-HA MAb
(12CA5) and walleye RACK1 was detected with anti-FLAG MAb (M2). HA-
tagged Orf B and FLAG-tagged walleye RACK1 run at approximately 39 kDa
and 37 kDa, respectively. Lysates represent 4% of the total amount used for
immunoprecipitation. B. Immunoprecipitation of Orf B with endogenous
walleye RACK1. Lysates from walleye cells (W12) transfected with pKH3–Orf
B or pKH3 empty vector were immunoprecipitated with MAb to human
RACK1. Orf B was detected with anti-HA (12CA5).blots probed with antibodies to HA to detect Orf B or to FLAG
to detect walleye RACK1. Results in Fig. 4A demonstrate coIP
of Orf B and walleye RACK1 from HeLa cell lysates. Further,
an interaction of Orf B with walleye RACK1 was confirmed in
walleye fibroblast cells (W12). Cell lysates from W12 cells
transiently transfected with pKH3-Orf B or the pKH3 empty
vector were subjected to IP with an anti-RACK1 monoclonal
antibody. Western blot analysis demonstrates coIP of HA-tagged
OrfBwith endogenouswalleyeRACK1 (Fig. 4B). Together, these
data show that WDSVOrf B interacts with RACK1 in these cells.
WDSV Orf B associates with PKCα
Based on the known interaction of RACK1with conventional
PKC isoforms and the data above demonstrating binding of
RACK1 toWDSVOrf B, we investigated the possibility that Orf
B may be in a complex with PKC in the NIH3T3–Orf B cell line.
NIH3T3 mouse fibroblast cells only express PKC isozymes α, δ,
ɛ, and ζ (Mischak et al., 1993; Olivier and Parker, 1992).
Therefore, we tested possible interaction of Orf B with the
conventional isoform, PKCα. Lysates from NIH3T3–Orf B and
NIH3T3 control cells were subjected to IP with anti-PKCα
antibody and Orf B was detected with anti-HA antibody byFig. 6. WDSV Orf B-expressing cells remain viable after treatment with
staurosporine. NIH3T3 and NIH3T3–Orf B cells were treated with 25, 50, or
100 nM staurosporine, and cell viability was measured byMTS assay after 16 h of
incubation. The mean±standard deviation of OD490 readings from replicates of
six wells was determined and normalized to % viability. The data represent one of
three independent experiments. Statistically significant differences (Pb0.004).
Fig. 8. Orf B-expressing cells proliferate and survive in the absence of serum.
A. NIH3T3 cells and NIH3T3–Orf B cells were grown under serum-free
conditions and viable cells measured each day for 7 days by MTS assay. The
mean of six replicate wells was determined for each time point. Viable cells at
Day 0 were normalized to 100% and ODs from subsequent days were adjusted
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contrast, antibody that recognizes one of the novel PKC isoforms,
PKCδ, was unable to coIPOrf B from these lysates (Fig. 5). CoIP
of Orf Bwith another conventional isoform of PKC, PKCβII, has
been demonstrated with lysates harvested from Orf B-expressing
HeLa and CHO cells (data not shown).
The PKC family of serine/threonine kinases functions to
transduce signals that control cell proliferation, differentiation,
motility, and apoptosis. Activation of PKCα protects cells from
apoptosis (Nakashima, 2002; Ruvolo et al., 1998). The
interaction of Orf B with RACK1 and PKCα suggested that
PKC function might be altered. To evaluate whether Orf B
expression affects PKC function in NIH3T3–Orf B cells, we
first tested the ability of cells to survive after exposure to
staurosporine, a known PKC inhibitor and inducer of apoptosis.
Treatment of cells with concentrations of staurosporine that
induce apoptosis significantly reduced the number of viable
NIH3T3 cells compared with NIH3T3–Orf B cells (Pb0.004).
Exposure to 25, 50, or 100 nM staurosporine for 16 h reduced
NIH3T3 viability to 81% (mean±8.22), 79% (±5.07), and 71%
(±10.84) of untreated cells, respectively (Fig. 6). In contrast, the
viability of staurosporine-treated NIH3T3–Orf B cells was not
reduced relative to untreated cells (mean=104% at 25 nM (±5.4),
102% at 50 nM (±15.3), and 100% at 100nM (±14.6)). Com-
parable results were obtained when Orf B-expressing Cf2Th cells
were treated with staurosporine (data not shown). These results
suggest that Orf B associates with conventional PKC isoforms
and may affect PKC signaling to promote cell survival.
PKC is activated in WDSV Orf B-expressing cells
Newly synthesized PKC associates with cellular membranes
through weak interactions with phospholipids. PKC thenFig. 7. PKCα is constitutively activated in Orf B-expressing cells. NIH3T3 and
NIH3T3–Orf B cells were grown without serum for 24 h and then treated with
dimethyl sulfoxide (DMSO), bisindolymaleimide I (Bim), or phorbol ester
(PMA). Cell lysates were harvested, separated into membrane (A) and cytosolic
(B) fractions by ultracentrifugation, and analyzed by western blot with the
indicated antibodies; anti-pPKCα detects PKCα when phosphorylated at thre-
onine 638, anti-PKCα detects total PKCα, anti-RACK1 detects endogenous
RACK1, and anti-HA (12CA5) detects HA-tagged Orf B. β-actin and cadherin
serve as loading controls. The data presented in this figure is representative of
four independent experiments.
accordingly. The data presented in this figure is representative of three
independent experiments. B. Phase contrast images of NIH3T3 and NIH3T3–
Orf B cells illustrate cell morphology at day 0 and day 3 of culture without
serum. Magnification was 200×.undergoes phosphorylation at three sites rendering it mature
and catalytically competent but not yet fully active. Phosphory-
lated PKC is released into the cytosol where it remains in an
inactive conformation until elevated levels of Ca+2 and DAG are
present, at which time PKC translocates to the membrane. High
affinity interactions of PKC with the membrane result in the
release of the PKC pseudosubstrate from the substrate binding
site and the establishment of an active conformation of PKC
(Newton, 2003). Interaction of RACK1 with activated PKC
targets PKC to different subcellular sites close to PKC substrates
and is thought to maintain PKC in its active conformation.
To determine whether Orf B affects activation of PKCα due
to its interaction with RACK1 the activation status and
localization of PKCα was investigated. We focused on the
NIH3T3 fibroblast cell line for these studies, because, when
cultured under serum-deprived conditions, PKC is not activated
and the effect of overexpressed RACK1 on cell growth has been
extensively investigated (Chang et al., 2001, 1998; Mamidipudi
et al., 2004). Cell lysates were isolated from NIH3T3 and
NIH3T3–Orf B cells that were serum-deprived for 24 h and
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dimethyl sulfoxide (DMSO), a phorbol ester known to activate
PKC, or with an equal volume of DMSO as control. Cytosolic
and membrane fractions were separated by ultracentrifugation
and subjected to western blot analysis with anti-phospho-PKC
α/βII antibody specific for the autophosphorylated sites of
PKCα (Thr 638) and PKCβII (Thr641). As expected, full
activation and translocation of PKCα to the membrane fraction
was only detected in serum-deprived NIH3T3 cells after PMA
treatment (Fig. 7A). In contrast, activated PKCα is present in
the membrane fractions from serum-deprived NIH3T3–Orf B
cells treated with PMA or with DMSO alone (Fig. 7A). The
same blot was probed with antibody against the membrane
glycoprotein cadherin as a loading control. The blot was then
reprobed for total PKCα. The majority of PKCα detected in the
membrane fraction from serum-deprived NIH 3T3–Orf B cells
appears to be phosphorylated whereas only unphosphorylated
PKCα was detected in membranes of NIH3T3 cells. EquivalentFig. 9. Activated PKC drives proliferation and survival of Orf B-expressing cells. A.
DMSO (NIH3T3–Orf B no serum+Bim) or DMSO only (NIH3T3–Orf B no serum). N
B serum+Bim). Viable cells were measured each day for 7 days by MTS assay. The
Day 0 were normalized to 100% viability and the ODs from subsequent days were
independent experiments. B. Phase contrast images illustrate the morphology NIH3T3
serum and treated with DMSO (middle), and cells without serum and with 5 µM Blevels of phosphorylated PKCα were detected in NIH3T3 and
NIH3T3–Orf B cells treated with PMA (Fig. 7A), and phos-
phorylated PKCα were detected in cytosolic fractions isolated
from NIH3T3 and NIH3T3–Orf B cells (Fig. 7B). Treatment of
cells with PMA resulted in reduced levels of cytosolic, phos-
phorylated PKCα, suggesting that PKCα translocated to the
membrane. Expression of Orf B and RACK1 in membrane and
cytosolic fractions was confirmed by staining the lower portion
of the blots with anti-HA and anti-RACK1 and with anti-β actin
as a loading control (Fig. 7A and B).
Next, we assessed the effect of treatment with the PKC
inhibitor bisindolymaleimide I hydrochloride (Bim) on PKCα
activation in NIH3T3–Orf B cells. Bim binds to the catalytic site
of PKC and functions as a competitive inhibitor of ATP (Toullec
et al., 1991). Cells were serum-deprived for 24 h and then treated
with Bim for 2 h, and lysates collected and processed as above.
Treatment with Bim resulted in greatly reduced levels of
activated PKCα in membrane preparations from serum-deprivedNIH3T3–Orf B cells were grown without serum in the presence of 5 µM Bim in
IH3T3–Orf B cells were also cultured with serum and 5 µM Bim (NIH3T3–Orf
mean of six replicate wells was determined for each time point. Viable cells at
adjusted accordingly. The data presented in this figure is representative of three
–Orf B cells cultured with serum and treated with 5 µM Bim (left), cells without
im (right) at day 0 and day 3. Magnification was 200×.
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constitutively activated in Orf B-expressing cells.
Activation of PKC in NIH3T3–Orf B cells promotes cell survival
PKC regulates several signaling pathways that mediate cell
proliferation and survival. Since PKCα is constitutively activated
in Orf B-expressing cells under serum-deprived conditions, we
investigated whether activation of PKCα in NIH3T3–Orf B cells
influences cell survival. After culture of NIH3T3–Orf B and
NIH3T3 control cells for 24 h in the presence of serum, cells were
washed with phosphate buffered saline (PBS) and further
cultured in media without serum. An MTS assay was used to
measure cell growth. The MTS reagent was added to the culture
each day and OD490 readings were taken after 3 h of further
incubation. Total cell input at day 0, when serum was removed,
was normalized to a value of 100% viability and adjusted
accordingly each day thereafter for 7 days. The growth of
NIH3T3 cells declined progressively through day 7 without
serum (Fig. 8A). The phase contrast image presented in Fig. 8B
illustrates substantial cell loss by day 3. In contrast, proliferation
of NIH3T3–Orf B cells was observed through day 3, during
which time 1.7 cell doublings occurred (Fig. 8A). A slight
decrease in cell viability was observed at days 4 and 5, after
which there was increased proliferation of NIH3T3–Orf B cells
through day 7 without serum. NIH3T3–Orf B cell proliferation is
shown in the phase contrast images at day 0 and 3 days after
serum deprivation (Fig. 8B).
To determine whether activated PKC is responsible for the
proliferation and survival of NIH3T3–Orf B cells shown in
Fig. 8, cells were cultured in the presence of the PKC inhibitor,
Bim. The growth of serum-deprived NIH3T3–Orf B cells was
significantly diminished in the presence of Bim (Fig. 9A, open
squares, Pb0.001). After 3 days of treatment there were 60%
fewer NIH3T3–Orf B cells than in cultures without Bim. By
day 7 the number of viable cells in the Bim treated cultures was
reduced to input levels (mean=90%±7.9), whereas the cultures
without Bim remained elevated (mean=316%±39). The de-
crease in cell growth is evident in the phase contrast images
shown in Fig. 9B (compare middle panels vs. right panels).
Addition of Bim to NIH3T3–Orf B cells cultured in the presence
of serum had no effect on the ability of these cells to proliferate
(Fig. 9A and B, left panels). Overall, these results support the
conclusion that PKCα is activated in NIH3T3–Orf B cells and
that this activation contributes to cell proliferation and survival.
Discussion
The results from these studies demonstrate the interaction of
WDSV Orf B with RACK1 and PKCα. RACK1 was identified
as a binding partner of WDSV Orf B by a yeast 2 hybrid screen
and this interaction was confirmed by coIP assays. RACK1 is
known to interact with over 20 cellular and viral proteins with
varying functions (McCahill et al., 2002). Cloned walleye
RACK1 exhibits 96% amino acid identity to human and mouse
RACK1 and 97% identity to zebrafish RACK1, illustrating the
highly conserved nature of this protein. The functional im-portance of RACK1 is exemplified by this conservation across
eukaryotic species (McCahill et al., 2002). RACK1 was first
identified as an anchoring protein for the conventional PKCs and
activated PKC βII was the preferred binding partner of RACK1
(Csukai and Mochly-Rosen, 1999; Mochly-Rosen et al., 1991a,
b; Mochly-Rosen et al., 1995; Ron et al., 1994; Stebbins and
Mochly-Rosen, 2001). One of the novel PKC isoforms, PKCɛ, is
known to interact with RACK2, also known as the coatomer
protein β'COP (Csukai et al., 1997). The expression pattern for
each PKC isoform varies among different cell types (Jaken,
Leach, and Klauck, 1989; Mochly-Rosen et al., 1990). NIH3T3
cells express abundant levels of only one conventional PKC
isoform, PKCα, and low levels of the novel forms, PKCδ and
PKCɛ (McCaffrey et al., 1987; Mischak et al., 1993).
The interaction of Orf B with RACK1 suggested that PKC
may be present in an Orf B/RACK1 complex, and coIP assays
with lysates from NIH3T3–Orf B cells confirmed an interaction
of Orf B with PKCα. Orf B was also coIPed with PKCβII from
lysates isolated from cells that express this isoform. An asso-
ciation of Orf B and PKC is further suggested by the localization
of Orf B in tumor cells at the plasma membrane and along actin
stress fibers. Goodnight et al. (Goodnight et al., 1995) showed
that PKCα is diffusely distributed in the cytoplasm in NIH3T3
cells and, upon TPA stimulation, is redistributed to the plasma
membrane with marked localization to membrane ruffles and
accumulation at focal adhesion contacts. RACK1 is also targeted
to focal adhesions where it affects cell motility (Kiely et al.,
2006; Vomastek et al., 2007). When over-expressed in NIH3T3
cells, PKCβII associates with actin-rich microfilaments (Good-
night et al., 1995). The localization of Orf B in explanted tumor
cells and cultured cell lines exhibited all of these characteristics.
Still unresolved is the question of whether there is direct
contact between Orf B and PKCα or whether coIP is dependent
on the interaction of Orf B and RACK1. RACK1 holds PKC in
an active conformation, and the structural nature of RACK1
indicates that more than one proteinmay bind to it concomitantly
(McCahill et al., 2002). The presence of Orf B in a RACK1/PKC
complex may aid in the formation of a more stable, active
complex. Another possibility is that Orf B is a substrate for PKC
and RACK1 targets PKC to subcellular locations in which Orf B
resides. A ProSite Motif analysis (Hulo et al., 2008) identified
three predicted PKC phosphorylation sites within Orf B.
Binding of viral proteins to RACK1 may be a means to target
interaction with PKC. The Epstein–Barr virus protein, ZEBRA,
is a transcriptional activator that functions to disrupt latency.
ZEBRA binds RACK1 and is phosphorylated by PKC at residue
S186. However, this phosphorylation does not appear to be
responsible for the disruption of latency (El-Guindy et al., 2002).
PKC activity was inhibited in EBV-infected monocytes, likely
due to impaired translocation of PKC from the cytosol to the
plasma membrane (Tardif et al., 2002). The M1 protein from
avian, swine, and human influenza A viruses interacts with
RACK1 and is phosphorylated by PKC (Reinhardt and Wolff,
2000). HIV Nef also binds RACK1 and is phosphorylated by
PKC, which results in enhanced viral replication (Gallina et al.,
2001; Wolf et al., 2008). The phosphorylation status of Orf B
will be the subject of future investigations.
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targeted for phosphorylation at the activation loop by PDK-1,
followed by autophosphorylation at the turn and hydrophobic
motifs, and release into the cytosol in an inactive conformation.
Extracellular stimuli elevate the levels of intracellular Ca+2 and
DAG, which facilitates translocation of cytosolic PKC to the
membrane and results in high affinity interactions (Newton,
2003). Activated PKC was only detected after stimulation of
serum-deprived NIH3T3 cells with PMA. PMA binds PKC and
recruits it to the membrane. Detection of phosphorylated PKCα
in membranes of serum-deprived NIH3T3–Orf B cells, without
PMA treatment, indicates that it is in a constitutively active
conformation. Activated PKC functions to phosphorylate and
activate substrate proteins that affect cell survival and growth.
Tethering of active PKC to the membrane allows binding to
substrates, which affect downstream targets important in cell
proliferation such as Raf-1 and the mitogen-activated protein
kinase kinase-extracellular signal-regulated kinase (MEK-
ERK) (Cai et al., 1997). In HL60 cells PKCα co-localizes
with and phosphorylates Bcl-2 in mitochondria, resulting in
increased cell survival following chemotherapy (Ruvolo et al.,
1999). Constitutive expression of Orf B resulted in cell survival
after treatment with staurosporine and proliferation and survival
of cells cultured under serum-deprived conditions. The
constitutive activation of PKCα in these cells suggests that it
is responsible for Orf B's effects. The reversal of these effects
by treatment of serum-deprived cells with Bim confirmed the
requirement for the PKC signaling pathway in this process.
WDSV transcripts encoding the Orf B protein are present
during the period of tumor development, and results from these
studies suggest that Orf B is tumorigenic. Constitutive activation
of PKCα in WDSV infected cells could lead to deregulated cell
signaling pathways critical for both apoptosis and cell prolifera-
tion and resulting in tumor formation. The evidence presented
here demonstrates alterations of cell proliferation and response to
apoptotic stimuli, specifically subject to a PKC inhibitor, in cells
expressing Orf B. Identification of the downstream targets
activated in Orf B-expressing cells will provide valuable insight
into the mechanism(s) of WDSVoncogenesis.
Materials and methods
Cells and transfection
TheWDSV orf b coding sequence was cloned into the pKH3
vector (a generous gift from Dr. Jun-Lin Guan, Cornell
University) as previously described (Rovnak et al., 2001).
The pKH3 vector contains a CMV promoter and fuses three
influenza virus hemagglutinin (HA) tags onto the amimo
terminus of the expressed protein (Chen et al., 1996; Mattingly
et al., 1994).
NIH3T3 cells (ATCC CRL 1658), Cf2Th cells (ATCC CRL
1430), and HeLa cells (ATCC CCL 2) were maintained in
Dulbecco's modified Eagle medium (DMEM) with 10% fetal
bovine serum (FBS) at 37 °C in 5% CO2. CHO cells (CHO-K1,
ATCC CCL 61) were maintained in Ham's F12 medium
supplemented with 10% FBS. Cells were transfected usingFuGENE6 (Roche) according to the manufacturer's instruc-
tions. Stable cell lines were established by cotransfection of
pKH3–Orf B and a plasmid encoding neomycin resistance
pMC1neo (Stratagene). Cells were selected with G418 and
single colonies were expanded and assayed for Orf B expression
by western blot analysis.
Fluorescence microscopy
Cells cultured from a regressing dermal sarcoma and NIH3T3
cells were grown on glass slides for immunofluorescence assays
(Cel-Line; Erie Scientific, Inc) (Rovnak et al., 2007). Slides were
fixed in 2% buffered formalin for 15 min, rinsed in phosphate
buffered saline (PBS), and fixed for 5 min in cold acetone:
methanol (1:1 v/v). Fixed cells were incubated with a 1:100
dilution of affinity purified rabbit anti-Orf B sera (kindly provided
by Volker Vogt, Department of Molecular Biology and Genetics,
Cornell University) or 1:1000 dilution ofmousemonoclonal anti-
HA antibody (HA.11, Covance) for 1 h at 37 °C in a humidified
chamber. Slides were washed in PBS and incubated with a 1:40
dilution of affinity purified goat anti-rabbit IgG or goat anti-
mouse IgG conjugated to fluorescein isothiocyanate (FITC).
After washing in PBS, slides were stained for 1 min in 300 µM
4′,6′-diamidino-2-phenylindole (DAPI). Photomicrographs were
captured digitally at a magnification of 200× or 400× and images
were assembled with Adobe Photoshop 7.0 software.
Yeast 2-hybrid screening
WDSV orf b was amplified by PCR from the plasmid clone
pKH3-Orf B using 5′ and 3′ primers that incorporate EcoRI (5′-
GCCGAATTCATGTTTTCAGACTCAGATTCCT-3′) and
BamHI (5′-GCCGGATCCTTACTCCGTAGGGCTGGGCTCT-
3′) restriction sites, respectively. The amplified product was
digested and ligated into the GAL4 DNA binding domain vector
pAS2-1 and used as the bait to screen a pACT2 GAL4 AD fusion
HeLa cDNA library (MATCHMAKER GAL4 Two-Hybrid
System, Clontech). Saccharomyces cerevisiae strain Y190 was
co-transformed with the bait plasmid, pAS2-1-Orf B and the
pACT2 cDNA library. Positive clones were initially selected
based on the ability to grow in the absence of histidine, leucine,
and tryptophan in the presence of 25 mM 3-amino 1, 2, 4-triazole
(3-AT). Positive colonies were further screened for β-galactosi-
dase activity by a colony-lift assay. Plasmid DNA was isolated
from clones positive for β-galactosidase activity and sequenced.
The specificity of the Orf B and RACK1 interaction was shown
by transformation of yeast with (1) pAS2-1-Orf B and pACT2
plasmid, (2) pAS2-1 and pACT2RACK1 plasmid, which were
negative for β-galactosidase activity. In addition, screening of the
same cDNA library with another viral protein, WDSV rv-cyclin
did not result in any interaction with RACK1 (Quackenbush,
unpublished).
Cloning of walleye RACK1
RNAwas isolated from awalleye fibroblast cell line (W12) with
RNAzol (Tel-Test, Inc.) and cDNAs were prepared with oligo dT
558 C.C. Daniels et al. / Virology 375 (2008) 550–560primer and Superscript II according to instructions of the man-
ufacturer (Life Technologies). An internal walleye RACK1
(wRACK1) sequence was amplified from W12 cDNA by PCR
using degenerate primers designed from highly conserved regions
of zebrafish, pufferfish, human, and mouse RACK1 sequences (5′
primer— ATGACYGAGCARATGACMST; 3′ primer—
CKNGTDCCRATRGTBCACCTG). Additional walleye RACK1
5′ sequences were amplified using a walleye specific RACK1
primer A (5′-AGTTGGCCAGATTCCACACCTTCAC-3′) and a
primer designed from zebrafish RACK1 (5′-ATGACCGAGCA-
GATGACAGTAAGGG-3′). The remaining unknown 5′ wall-
eye RACK1 sequence was amplified by RNA ligase-mediated
and oligonucleotide capping rapid amplification of cDNA ends
(RACE) using the 5′RACE primer and the wRACK1 specific
primer B (5′-GTCTGGAAACTGCGGGGTCGTGGC-3′) ac-
cording to manufacturers instructions (GeneRacer Kit, Invitro-
gen). The 3′ end of wRACK1 was amplified with an oligo dT
primer and wRACK1 specific primer C (5′-GATGGACAGGC-
CATGCTTTGGGAT-3′).
Walleye RACK1was amplified by PCR from oligo dT primed
W12 cDNA using walleye RACK1 specific primer D (5′-
GCCGAATTCGATGACCGAGCAGATGACCGTGAGA-3′)
and primer E (5′-CGGGGATCCTTATCGGGTTCCGACGGT-
CACCTG-3′) that incorporate EcoRI and BamHI restriction sites.
The amplified product was digested with EcoRI and BamHI and
ligated into p3XFLAG-CMV™-10 expression vector (Sigma).
Nucleotide sequence accession number
The final cDNA sequence for walleye RACK1 has been
assigned GenBank accession number EU290652.
Immunoprecipitation and western blot analysis
NIH3T3 control cells and NIH3T3 cells stably expressing Orf
B (NIH3T3–Orf B) were lysed with immunoprecipitation (IP)
buffer (1% Triton X-100, 0.5% NP-40, 150 mM NaCl, 10 mM
Tris–HCl [pH 7.5], 1 mM EDTA [pH 8.0], 1 mM EGTA,
0.2 mM sodium orthovanadate, 0.2 mM PMSF, 2 μg/ml of
leupeptin and aprotinin, 1 μg/ml pepstatin). Lysates were
centrifuged at 21,000 ×g for 10 min and protein concentration
of supernatants was determined with the Micro BCA Kit
(Pierce). 500 μg of cell lysates were diluted to a concentration of
1 μg/ml in IP buffer and precleared for 3 h with 50 μl of a
suspension of Protein G-Sepharose (Pharmacia Biotech). One
microgram of antibody was added to the precleared lysates and
incubated overnight at 4 °C with rotation. Fifty microliters of a
Protein G suspension was added and incubated for an additional
3 h at 4 °C with rotation. Protein G pellets were washed three
times with cold IP buffer, suspended in 20 μl of SDS-PAGE
loading buffer, and heated to 70° for 10 min. Samples were
separated under denaturing conditions in a 10% polyacrylamide
gel. Cell lysates (15 μg of protein) were loaded in control lanes.
Denatured proteins were transferred to Immobilon-P-membrane
(Millipore) and incubated with primary antibody overnight at
4 °C. Blots were washed, incubated with anti-rabbit IgG or anti-
mouse IgM antibodies conjugated with horseradish peroxidase,and developed with LumiGLO Chemiluminsescent Substrate
Kit (Kirkegaard and Perry Laboratories).
Membrane protein fractionation
NIH3T3 and NIH3T3–Orf B cells were plated at 7.5×105
cells/ml and grown in DMEM containing 10% FBS supplemen-
ted with 4 mM glutamine. Twenty four hours after plating, the
growth medium was replaced with DMEM without serum for
24 h. Cells were then treated with DMSO, for 45 min, 200 nM
phorbol 12-myristate 13-acetate (PMA) for 45 min, or 5 μM
Bisindolymaleide I (Bim) for 2 h and then cells were immediately
placed on ice. Cells were scraped into protein lysis buffer lacking
detergent (20 mM Tris [pH7.5], 2 mM EDTA, 2 mM EGTA,
1 mM PMSF, 2 ug/ml leupeptin, 2 ug/ml aprotinin, 0.1% 2-
mercaptoethanol) then sonicated briefly as described in Good-
night et al. (Goodnight et al., 1995). Membrane and cytoplasmic
fractions were separated by ultracentrifugation at 100,000 ×g for
1 h at 4 °C. The supernatant (cytoplasmic fraction) was collected.
The pellet (membrane fraction) was resuspended in protein lysis
buffer containing 1.2% Triton X-100, sonicated briefly and
centrifuged at 20,000 ×g for 10 min at 4 °C and the supernatant
collected and analyzed as the membrane fraction. Protein
concentrations were determined using the Micro BCA Kit
(Pierce). Fifteen micrograms of cytoplasmic proteins were
precipitated in 1/10 volume of trichloroacetic acid (Sigma) and
pellets were dissolved in 100 mM NaOH.
Cell viability assays
NIH3T3 andNIH3T3–OrfB cellswere plated at 5.0×105 cells/
ml in 96 well plates and incubated for 24 h in DMEM containing
10% FBS. Staurosporine was added to final concentrations of 25,
50, and 100 nM, incubated for 16 h at 37°C, and cell viability was
measured using CellTiter 96 AQueous One Solution (Promega)
according to manufacturer's instructions. Briefly, 20 μl of
CellTiter 96 solution was added to each well, incubated for 3 h
at 37°C, and then OD readings were taken at 490 nm.
NIH3T3 and NIH3T3–Orf B cells were plated at 5.0×105
cells/ml in 96 well plates containing DMEM with 10% FBS and
incubated at 37°C in 5% CO2. After 24 h of culture cells were
washed with PBS then further cultured in DMEM without
serum. Bim was added daily to maintain a final concentration of
5 µM. Cell viability was measured daily for 7 days using the
CellTiter 96 solution (Promega) as described above. Student's t
test and 95% confidence intervals based on a t distribution were
used for statistical analyses. A P value of less than 0.01 was
considered significant.
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